Biocryst Pharmaceuticals Inc.


+0.16 (+1.14%)

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low


52 wk hi




Burn Rate (Qtr)


Mkt Cap


Avg Volume


*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by



Company Profile

BioCryst is a late-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases.

Recent Posts

See what the community is saying - click to see full post.

Upcoming September 2020 COVID-19 Therapeutic Catalyst Event

BCRX - NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir